Last updated: 2026-09-07 13:25:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Charles River Laboratories International, Inc. (CRL) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NYSE. The stock is currently priced at $288.59, with a market capitalisation of $13.77B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $144.26 to $303.31. This page covers its latest market performance, valuation, price trends and company information.
$13.77B | |
$299.01 | |
$460.21 | |
$19.92 | |
$293.35 | |
594.79K | |
890.99K | |
-- | |
$303.31 | |
$144.26 | |
-- | |
-- |
Charles River Laboratories International, Inc. (CRL) last closed at $293.35 as of 2026-09-04 23:31:00, unchanged from the previous close of $293.35.
During the latest regular trading session, CRL traded between $19.92 and $460.21, with a volume of 594.79K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Charles River Laboratories International, Inc. (CRL) moved from $296.41 to $288.59, representing a decline of 2.64% ($7.82).
The stock traded between $280.91 and $303.31 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 763.56 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.7%
CRL is currently trading at $288.59, placing it 90.7% of the way from its 52-week low of $144.26 to its 52-week high of $303.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 19700 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Charles River Laboratories International, Inc. (CRL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.